Artificial pancreas achieves glycaemic control in type 2 diabetes says study

The researchers conducted a randomised, open-label trial conducted on general wards in two tertiary hospitals located in the UK and Switzerland. A total of 136 adults with type 2 diabetes on insulin participated in the study, with 70 assigned to receive the closed-loop insulin delivery and 66 continuing with their insulin therapy, according to local clinical practice.

The primary end point was the percentage of time that the sensor glucose measurement was within the target range of 100 to 180 mg per decilitre (5.6 to 10.0 mmol per litre) for up to 15 days or until hospital discharge.

Leave a Reply

Your email address will not be published. Required fields are marked *